1
|
Sears CL and Garrett WS: Microbes,
microbiota, and colon cancer. Cell Host Microbe. 15:317–328. 2014.
View Article : Google Scholar
|
2
|
Todaro M, Gaggianesi M, Catalano V,
Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S,
Cocorullo G, et al: CD44v6 is a marker of constitutive and
reprogrammed cancer stem cells driving colon cancer metastasis.
Cell Stem Cell. 14:342–356. 2014. View Article : Google Scholar
|
3
|
Terzić J, Grivennikov S, Karin E and Karin
M: Inflammation and colon cancer. Gastroenterology.
138:2101–2114.e5. 2010. View Article : Google Scholar
|
4
|
Shawki S, Ashburn J, Signs SA and Huang E:
Colon cancer: Inflammation-associated cancer. Surg Oncol Clin N Am.
27:269–287. 2018. View Article : Google Scholar
|
5
|
Wang K and Karin M: Tumor-elicited
inflammation and colorectal cancer. Adv Cancer Res. 128:173–196.
2015. View Article : Google Scholar
|
6
|
Ullman TA and Itzkowitz SH: Intestinal
inflammation and cancer. Gastroenterology. 140:1807–1816. 2011.
View Article : Google Scholar
|
7
|
Waldner MJ, Foersch S and Neurath MF:
Interleukin-6 - a key regulator of colorectal cancer development.
Int J Biol Sci. 8:1248–1253. 2012. View Article : Google Scholar
|
8
|
Lee YS, Choi I, Ning Y, Kim NY,
Khatchadourian V, Yang D, Chung HK, Choi D, LaBonte MJ, Ladner RD,
et al: Interleukin-8 and its receptor CXCR2 in the tumour
microenvironment promote colon cancer growth, progression and
metastasis. Br J Cancer. 106:1833–1841. 2012. View Article : Google Scholar
|
9
|
Barderas R, Bartolomé RA,
Fernandez-Aceñero MJ, Torres S and Casal JI: High expression of
IL-13 receptor α2 in colorectal cancer is associated with invasion,
liver metastasis, and poor prognosis. Cancer Res. 72:2780–2790.
2012. View Article : Google Scholar
|
10
|
Hyun YS, Han DS, Lee AR, Eun CS, Youn J
and Kim HY: Role of IL-17A in the development of colitis-associated
cancer. Carcinogenesis. 33:931–936. 2012. View Article : Google Scholar
|
11
|
Kanai T, Watanabe M, Hayashi A, Nakazawa
A, Yajima T, Okazawa A, Yamazaki M, Ishii H and Hibi T: Regulatory
effect of interleukin-4 and interleukin-13 on colon cancer cell
adhesion. Br J Cancer. 82:1717–1723. 2000.
|
12
|
Koller FL, Hwang DG, Dozier EA and
Fingleton B: Epithelial interleukin-4 receptor expression promotes
colon tumor growth. Carcinogenesis. 31:1010–1017. 2010. View Article : Google Scholar
|
13
|
Bankaitis KV and Fingleton B: Targeting
IL4/IL4R for the treatment of epithelial cancer metastasis. Clin
Exp Metastasis. 32:847–856. 2015. View Article : Google Scholar
|
14
|
Di Stefano AB, Iovino F, Lombardo Y,
Eterno V, Höger T, Dieli F, Stassi G and Todaro M: Survivin is
regulated by interleukin-4 in colon cancer stem cells. J Cell
Physiol. 225:555–561. 2010. View Article : Google Scholar
|
15
|
Liu H, Antony S, Roy K, Juhasz A, Wu Y, Lu
J, Meitzler JL, Jiang G, Polley E and Doroshow JH: Interleukin-4
and interleukin-13 increase NADPH oxidase 1-related proliferation
of human colon cancer cells. Oncotarget. 8:38113–38135. 2017.
|
16
|
Alla V, Engelmann D, Niemetz A, Pahnke J,
Schmidt A, Kunz M, Emmrich S, Steder M, Koczan D and Pützer BM:
E2F1 in melanoma progression and metastasis. J Natl Cancer Inst.
102:127–133. 2010. View Article : Google Scholar
|
17
|
Hsu EC, Kulp SK, Huang HL, Tu HJ, Chao MW,
Tseng YC, Yang MC, Salunke SB, Sullivan NJ, Chen WC, et al:
Integrin-linked kinase as a novel molecular switch of the
IL-6-NF-κB signaling loop in breast cancer. Carcinogenesis.
37:430–442. 2016. View Article : Google Scholar
|
18
|
Fang Z, Gong C, Liu H, Zhang X, Mei L,
Song M, Qiu L, Luo S, Zhu Z, Zhang R, et al: E2F1 promote the
aggressiveness of human colorectal cancer by activating the
ribonucleotide reductase small subunit M2. Biochem Biophys Res
Commun. 464:407–415. 2015. View Article : Google Scholar
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
20
|
Fang Z, Gong C, Yu S, Zhou W, Hassan W, Li
H, Wang X, Hu Y, Gu K, Chen X, et al: NFYB-induced high expression
of E2F1 contributes to oxaliplatin resistance in colorectal cancer
via the enhancement of CHK1 signaling. Cancer Lett. 415:58–72.
2018. View Article : Google Scholar
|
21
|
Formentini A, Braun P, Fricke H, Link KH,
Henne-Bruns D and Kornmann M: Expression of interleukin-4 and
interleukin-13 and their receptors in colorectal cancer. Int J
Colorectal Dis. 27:1369–1376. 2012. View Article : Google Scholar
|
22
|
Cao H, Zhang J, Liu H, Wan L, Zhang H,
Huang Q, Xu E and Lai M: IL-13/STAT6 signaling plays a critical
role in the epithelial-mesenchymal transition of colorectal cancer
cells. Oncotarget. 7:61183–61198. 2016. View Article : Google Scholar
|
23
|
Cavallo F, De Giovanni C, Nanni P, Forni G
and Lollini PL: 2011: The immune hallmarks of cancer. Cancer
Immunol Immunother. 60:319–326. 2011. View Article : Google Scholar
|
24
|
Prokopchuk O, Liu Y, Henne-Bruns D and
Kornmann M: Interleukin-4 enhances proliferation of human
pancreatic cancer cells: Evidence for autocrine and paracrine
actions. Br J Cancer. 92:921–928. 2005. View Article : Google Scholar
|
25
|
Conticello C, Pedini F, Zeuner A, Patti M,
Zerilli M, Stassi G, Messina A, Peschle C and De Maria R: IL-4
protects tumor cells from anti-CD95 and chemotherapeutic agents via
up-regulation of antiapoptotic proteins. J Immunol. 172:5467–5477.
2004. View Article : Google Scholar
|
26
|
Todaro M, Zerilli M, Ricci-Vitiani L, Bini
M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre
S, Di Gesù G, et al: Autocrine production of interleukin-4 and
interleukin-10 is required for survival and growth of thyroid
cancer cells. Cancer Res. 66:1491–1499. 2006. View Article : Google Scholar
|
27
|
Todaro M, Alea MP, Di Stefano AB,
Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G,
Medema JP, et al: Colon cancer stem cells dictate tumor growth and
resist cell death by production of interleukin-4. Cell Stem Cell.
1:389–402. 2007. View Article : Google Scholar
|
28
|
Leon-Cabrera SA, Molina-Guzman E,
Delgado-Ramirez YG, Vázquez-Sandoval A, Ledesma-Soto Y,
Pérez-Plasencia CG, Chirino YI, Delgado-Buenrostro L,
Rodríguez-Sosa M, Vaca-Paniagua F, et al: Lack of STAT6 attenuates
inflammation and drives protection against early steps of
colitis-associated colon cancer. Cancer Immunol Res. 5:385–396.
2017. View Article : Google Scholar
|
29
|
Li BH, Yang XZ, Li PD, Yuan Q, Liu XH,
Yuan J and Zhang WJ: IL-4/Stat6 activities correlate with apoptosis
and metastasis in colon cancer cells. Biochem Biophys Res Commun.
369:554–560. 2008. View Article : Google Scholar
|
30
|
Zhang M, Zhou Y, Xie C, Zhou F, Chen Y,
Han G and Zhang WJ: STAT6 specific shRNA inhibits proliferation and
induces apoptosis in colon cancer HT-29 cells. Cancer Lett.
243:38–46. 2006. View Article : Google Scholar
|
31
|
Vizcaíno C, Mansilla S and Portugal J: Sp1
transcription factor: A long-standing target in cancer
chemotherapy. Pharmacol Ther. 152:111–124. 2015. View Article : Google Scholar
|
32
|
Safe S, Imanirad P, Sreevalsan S, Nair V
and Jutooru I: Transcription factor Sp1, also known as specificity
protein 1 as a therapeutic target. Expert Opin Ther Targets.
18:759–769. 2014. View Article : Google Scholar
|
33
|
Hedrick E, Cheng Y, Jin UH, Kim K and Safe
S: Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4
are non-oncogene addiction genes in cancer cells. Oncotarget.
7:22245–22256. 2016. View Article : Google Scholar
|
34
|
Wierstra I: Sp1: emerging roles - beyond
constitutive activation of TATA-less housekeeping genes. Biochem
Biophys Res Commun. 372:1–13. 2008. View Article : Google Scholar
|
35
|
LaPorte SL, Juo ZS, Vaclavikova J, Colf
LA, Qi X, Heller NM, Keegan AD and Garcia KC: Molecular and
structural basis of cytokine receptor pleiotropy in the
interleukin-4/13 system. Cell. 132:259–272. 2008. View Article : Google Scholar
|
36
|
Murata T, Noguchi PD and Puri RK: IL-13
induces phosphorylation and activation of JAK2 Janus kinase in
human colon carcinoma cell lines: similarities between IL-4 and
IL-13 signaling. J Immunol. 156:2972–2978. 1996.
|